Get started

Biotechnology

What Lies Beyond the Cornfield's Horizon?The narrative of corn in the global agricultural scene is not merely about sustenance but a complex ballet of economics, innovation, and policy. This staple crop stands at the intersection of international trade, with U.S. farmers gaining a foothold in Mexico's market through a significant legal victory against GMO corn restrictions, highlighting the nuanced dance between technology and trade agreements. Meanwhile, Brazil's agricultural strategies reveal a shift towards leveraging corn for ethanol, showcasing a potential future where corn could play an even more pivotal role in sustainable energy solutions. In science and technology, the development of digital corn twins presents a frontier in crop breeding. This innovative approach could redefine how we think about plant resilience and efficiency, potentially leading to crops tailored to withstand the capricious whims of climate change. The challenge lies in translating theoretical models into practical, field-ready solutions that can benefit farmers and consumers alike. However, the journey isn't without its threats. The unexpected rise of corn leaf aphids in 2024 serves as a stark reminder of the ongoing battle with nature's unpredictability. Farmers are now challenged to anticipate and manage these pests, pushing the boundaries of traditional farming practices into more predictive, data-driven methodologies. This situation beckons a broader inquiry into how agriculture can evolve not just to react but preemptively adapt to ecological shifts. As we look beyond the cornfield's horizon, we see a landscape where policy, technology, and biology converge. The future of corn involves navigating this triad with foresight, ensuring that each step taken today not only secures current yields but also plants the seeds for a sustainable agricultural legacy. This exploration into corn's evolving role invites us to ponder how we can harness these developments for a future where food security and environmental stewardship walk hand in hand.
CBOT:ZC1!Long
by UDIS_View
LXRX PENNY BIOTECH SHORT SETUPNASDAQ:LXRX LXRX has gained over 100% in the past month However it appears to be forming a double top in a potential short trade setup on the two hour chart. The K/D crossover on the hot RSI oscillator provides confirmation. Short Sale Volume is rising in the past two days. Findamentals - LXRX has a new medication for heart failure a common medical problem with a massive market It recently launched a public offering to raise capital to fund general operations and in doing so diluted the share holders. The good news is it is unlikely to do another in the near term. An entry would be at the current price with a stop loss above the highest volume bar on the profile. The first target is the POC of the volume profile about a 15% price drop . The second target is the pivot low on August 1st for another 15% drop. Taking of 1/2 at each target yields an expected 23% return over a period of about 5 trading days since drops are faster than rises. The call options of mid September have low volumes so I will not consider them.
NASDAQ:LXRXShort
by AwesomeAvani
SMMT | Consolidation Almost Complete | LONGSummit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
NASDAQ:SMMTLong
by DivergenceSeeker
Could AI Unlock the Secrets of Life's Building Blocks?In a remarkable leap forward for biotechnology, scientists have unveiled MassiveFold, a revolutionary adaptation of Google DeepMind's AlphaFold that transforms our ability to understand protein structures. This groundbreaking system achieves what was once thought impossible: reducing protein structure prediction time from months to mere hours. By combining parallel processing with sophisticated optimization techniques, Université de Lille and Linköping University researchers have created a tool that democratizes access to one of science's most powerful capabilities. The implications of this advancement ripple across multiple industries, from pharmaceutical development to sustainable agriculture. MassiveFold's ability to rapidly decode protein structures – the fundamental building blocks of life – accelerates our potential to develop new medicines, enhance crop yields, and create more efficient biofuels. What makes this development particularly significant is its accessibility; the system operates efficiently on both modest computing setups and advanced GPU infrastructures, making it available to research teams worldwide. Perhaps most intriguing is MassiveFold's performance in real-world applications. During the prestigious CASP15-CAPRI blind structure prediction trials, the system demonstrated remarkable accuracy, sometimes surpassing the capabilities of its predecessor, AlphaFold3. This success, combined with its open-source availability, suggests we're entering a new era of biological understanding where the mysteries of protein structures – and thus the fundamental mechanics of life – become increasingly accessible to scientific exploration. As this technology continues to evolve, it promises to unlock new possibilities in everything from disease treatment to environmental conservation, potentially revolutionizing our approach to humanity's most pressing challenges.
NASDAQ:GOOGLong
by UDIS_View
$AMGN observationThis is just my observation, not advice. Technical: 1. Price touched the 200 SMA. 2. Price is corrected to 50% correction and slightly pumped after reaching the supportive zone. 3. Price reached the volume price of FRVP around 270$. 4. The correction nature of the latest candles in the blue box is obvious. 5. In the daily and 4H charts, the stock is almost in the oversold zone. 6. A significant divergence is observable on the daily chart. Fundamental: 1. P/E ratio: 34.4x (Not undervalued) 2. In November 2024, Amgen's Phase 2 study of MariTide showed a 20% average weight loss over 52 weeks in obese patients without diabetes. While promising, it fell short of analysts' 23–25% expectations, raising concerns about its competitiveness against treatments like Eli Lilly's Zepbound and Novo Nordisk's Wegovy. 3. On November 26th, after MariTide phase 2 announcement, the price was mixed but could be considered to have moved up impulsively. 4. On 5th December, Amgen announced to invest 1B for expansion. 5. NASDAQ:AMGN launched Pavblu as a rival of NASDAQ:REGN 's Eylea. 6. On December 7th, NASDAQ:AMGN out significant result for Blinatumomab. 7. Based on reports, NASDAQ:AMGN raises quarterly dividend 5.8%. 8. Analyst sentiments: 14 buy, 15 hold, 3 sell. Scenarios: We are in the correction with two main scenarios: 1. ABC correction has been completed and impulsive waves have been started so we should look for entry. 2. A correction wave has been completed, and we are now in the B wave correction. In this case, we should see another price drop on wave C. After then, we can look for long on around 78% correction and trendline.
NASDAQ:AMGNLong
by jack_the_real_trader
$REGN LongThis is just my observation, but not an advice. Technical: REGN touched its two strong trendline since 2020 and 2021. REGN reached the 50% correction since 2020. REGN is oversold daily and weekly. A significant divergence is observable on daily chart. Price touched SMA 200. Fundamental: P/E: 16.9x (moderate undervalue) Since last ATH NASDAQ:REGN has come up with wide ranges of successful clinical trial outcomes. Nonetheless, prices dropped due to competitive pressures on Eylea. Last week, after significant clinical trial results of Odronextamab and Poze-Cemdi, the market moved up. However, the price slid after the BoA's PT revision. Analyst sentiments: 17 buy, 7 buy, 1 sell (BoA) The long possibility is high from now on.
NASDAQ:REGNLong
by jack_the_real_trader
Can Pharma Innovation Rewrite Healthcare's Future?In the rapidly evolving landscape of medical technology, Eli Lilly emerges as a beacon of transformative potential, challenging conventional boundaries of pharmaceutical innovation. With a strategic masterstroke, the company has positioned itself at the forefront of medical breakthroughs, particularly in the revolutionary realm of weight loss and diabetes treatments. The remarkable Zepbound medication stands as a testament to this vision, demonstrating unprecedented efficacy by enabling patients to lose an average of 20.2% body weight - a figure that not only surpasses competitors but also represents a paradigm shift in medical intervention. The company's financial architecture is equally compelling, reflecting a meticulously crafted approach to growth and shareholder value. With a staggering market capitalization of $722 billion, a 27.4% revenue growth, and an impressive 80.9% gross profit margin, Eli Lilly transcends the traditional pharmaceutical business model. Its recent $15 billion share buyback program and consistent 54-year dividend payment history underscore a strategic philosophy that balances aggressive innovation with prudent financial management, creating a blueprint for sustainable corporate success. Beyond financial metrics and breakthrough medications, Eli Lilly represents something more profound: a vision of healthcare's future where technology, research, and human potential converge. The company's $3 billion manufacturing expansion, commitment to oncology research with drugs like Jaypirca, and continuous investment in cutting-edge medical solutions paint a picture of an organization that sees beyond immediate profit - an entity committed to reshaping human health through relentless innovation and scientific excellence. In an era of unprecedented medical challenges, Eli Lilly stands not just as a pharmaceutical company, but as a harbinger of hope, demonstrating how visionary thinking can transform global health landscapes.
NYSE:LLYLong
by signalmastermind
ATAI Life Sciences | ATAI | Long at $1.30ATAI Life Sciences NASDAQ:ATAI , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is fast approaching my selected historical simple moving average (SMA). Often, but not always, the closer the price gets to this line, the higher chance there is for a fast upward move. In anticipation of this move, NASDAQ:ATAI is in a personal buy zone at $1.30. A word of caution: this is a pure technical analysis play and this company is not expected to be profitable for many, many years... Target #1 = $1.75 Target #2 = $2.50 Target #3 = $2.95
NASDAQ:ATAILong
by WorthlessViews
$VKTX is about to FEAST! Don't miss out on this BioTech trade. 🚀 Here it is: Your Free Saturday Setup! 🚀 Just as promised, here is a detailed video analysis on NASDAQ:VKTX Viking Therapeutics! 🧬 This trade meets all the criteria of my "High Five Setup" trading strategy, backed by solid technical analysis. Also, it has the potential to return over 100% on your capital deployed. With more probabilities on our side, the likelihood of success is through the roof! 📈💥 Check it out, and let’s ride this wave together! 🌊 Stay tuned for more insights! 🔔 NFA #Trading #StockMarket #Biotech #Investing #HighFiveSetup
NASDAQ:VKTXLong
by RonnieV29
41
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name during the pandemic, now faces a pivotal moment. Activist investor Starboard Value has taken a $1 billion stake, signaling potential changes on the horizon. But what does this mean for Pfizer's future? The company that swiftly developed a COVID-19 vaccine now grapples with declining sales and a tumbling stock price. Starboard's involvement brings both challenge and opportunity. Will this be the catalyst for Pfizer's renaissance or a sign of deeper troubles ahead? Former Pfizer executives have been approached to assist in the turnaround effort. Their potential involvement adds an intriguing layer to this unfolding story. Could their experience and insight be the key to unlocking Pfizer's next chapter of success and innovation? As the pharmaceutical landscape evolves post-pandemic, Pfizer's response to this pressure could set industry trends. Cost-cutting, strategic refocusing and potential leadership changes loom large. How will these moves impact drug development, patient care, and the broader healthcare ecosystem? For investors, patients, and industry watchers, Pfizer's next moves are crucial. Will the company emerge stronger, leaner, and more innovative? Or will it struggle to find its footing in a rapidly changing market? The answers to these questions could reshape the future of global healthcare.
NYSE:PFELong
by signalmastermind
2
MHUA Chinese Med Tech Penny StockMHUA is shown here on the daily chart. It is currently trading at about 90% off its high of the year. It is in the high volume area of the long term volume profile suggesting there is sufficent liquidity to support active trading. Recent volume spikes suggest buying volume increases with the spikes being about 10X relative volume. Price is over the POC line of the volume profile demonstrating that buying pressure exceeds selling pressure. Price is at or near to one standard deviation below the mean anchored VWAP and so in the undervalued area as confirmed by the RSI Stochastic < 20 %. Chart patterns include an engulfing " big ass " candle on 5/1 and a three-bar strike with another engulfing green candle on 5/12. Both of these could be considered long entry signals especially when supported by the price above the POC and the RSI. I will take a position risking 0.25% of the trading account to begin the trading week. I am targeting a gain of $15.00 per share being a 50% retracement back to the high YTD and a 300% return on investment. I will take a 100 share position and close 10 shares each time the price rises by $2.00. This will adequately mitigate the risk of a volatile penny stock while adequately rewarding the risk taken.
NASDAQ:MHUALong
by AwesomeAvani
KRRO a biotech company with earnings coming LONGKRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods . A recent analyst gave it an upside to 100 which is very favorable given its product line and track record with an all-time high of about $250 ( which is about 450% over current valuation) On the one-hour time frame, it has had a great week and is breaking out over its moving averages as well as bullish momentum on the dual TF RSI indicator. This is a stock-long trade in the biotechnology sector which is prognosticated to be among the best of 2024. The dramatic reversal on the chart tells me this is a long entry. Targeting $57.5 in the short term and $75.00 for most of the position in consideration of the analyst report.
NASDAQ:KRROLong
by AwesomeAvani
1
VTYX- a risky biotechnology penny stock LONGVTRX is on a 120 minute chart, currently trading at 90% off its ATH and 50% above its absolute long term support level. Price tried to cross above the long term mean VWAP 3 months ago but was rejected. I anticipate that in time it will try to so so again. From 3.3 to a target of 9 would be a move in the neighborhood of 300%. I will take a small position long trade here. This will be highly volatile. I will place a 25% stop loss to give VTRX room to roam for a couple of earnings periods. Once the price rises 25% I will convert to a trailing stop loss of 25% and make the then risk free trade low maintenance.
NASDAQ:VTYXLong
by AwesomeAvani
VOR - a b iotechnology penny stock LONGVOR is a on daily chart. It is a biotechnology startup which is burning cash. As a resut this is a speculative long trade for this company with products to treat leukemia ( blood cancer). Price has crossed over the POC line of the volume profile and also completed an anchored mean VWAP cross over. The Price Momentum Oscillator is reversing and buying volume has increased since the earnings report showed less of a loss than forecasted. I see 30% upside to the high pivot in mid-January. In conjunction with stop- loss set at the mean anchored VWAP this is a R to r of about 3.
NASDAQ:VOR
by AwesomeAvani
LCTX gets upgrade and is technically setup LONGLCTX on the weekly chart here has been falling since late 2021 and found support at the bottom of the high volume area of the volume profile and ranged between it and the POC line for the past 18 months. The is a high end clinically active biotechnology firm using stem cells to produce therapeutic cell lines . ( One experiment using the mammary glands of cows imbedded with cells that make insulin to make a weak milk solution containing insulin and then concentrate it for cheap insulin is quite remarkable- ) How about some special milk for to have with your sugar buzz) see more in the here link en.wikipedia.org Anyway, price rose into triple confluence- the anchored mean VWAP, the POC line, the upper boundary of the high volume area. A new analysis targets 7. Smart money is paying attention. My smart money is paying a lot of attention. I understand the science and the market that LCTX could reach in due time. I am not an insider but close. Enough said. My target is the tweezer tops of 2022 at 2.5 and so 65-70% upside in the near to intermediate term and after that maybe the analysis will revise the target up or down I am guessing the former.
AMEX:LCTXLong
by AwesomeAvani
VTYX- Buy the Pullback after a massive Bullish Surge LONGVTYX is an illustrative case in the trend is your friend. VTTX warmed up on Frbruary 20th and went parabolic on the next day and then faded while the moving averages and VWAP lines caught up. This is a buyable dip. It has now printed a couple of engulfing bullish candles. VTYX did less than a full 0.5 retracement as a sign of strength. I will take a long trade here targeting 16% upside to the top pivot of the recent price action. If the price can reach the target I will take half screening for higher-than-normal volatility. At present the volatility has mildly popped over the running mean telling me the continuation is on the ready. The plus here is earnings will report on March 24th so there is one month for traders to run the price up on this stock in that anticipation. Options are avaiable for call contracts expiring March 15th.
NASDAQ:VTYXLong
by AwesomeAvani
JAN on watch for bullish continuation LONGJAN had earnings but I cannot find the report. It is trading with heavy volume and it shows in the price action. Price has pulled back in the after-market in a standard Fibonacci retracement. A pullback is appropriate here as price has gained 250% in a month. I see the pullback as healthy and JAN is now well positioned for another bullish continuation. Volatility and volume supports the conclusion. I will set a stop loss at 10% and targets at 50%, 75% and 100% to take partial profits on an anticipated trend up. Alerts will be set onto a set of moving averages on the 30 minute time frame to detect death cross unders. Once profit is hits 10% I will change the stop loss to a trailing 10% stop loss and once above 75% make the trailing loss 5% and once over 100% change it to 3% so I can let the trade run itself from those orders.
JLong
by AwesomeAvani
2
LVTX a possible continuation medical technology penny stock LONGLVTX is a pharmaceutical company focused on biologicals for advanced prostate carcinoma. It recently secured a collaboration agreement with Merck to assist in the clinical trials and the financial burdens it imposes in a quid pro quo related to a share of product margins in the future. On the 15-minute chart, LVTX burst out of a long-standing consolidation cycle. The majority of shareholders per Yahoo Finance are insiders and institutions primarily hedge funds. These people are not clueless. This is a huge money inflow into the market cap. I intend to follow the money as I see that price has retraced to a good Fibonacci level and with the last candle may be on a reversal. I know that institutions tend to buy at the VWAP heavily and as price is below VWAP the impetus is to buy discounted from VWAP. I will follow the wisdom, experience and expertise of institutional traders. I will go long and assume the risk of more of a drop with an ATR stop loss. My goal in the trade is to get a 20% gain by the close on Monday. Getting into an insider trading move is tricky but it is interesting and can be profitable.
NASDAQ:LVTXLong
by AwesomeAvani
VERX ATH on Earnings LONGVERX on the 15 minute chart demonstrates printing a high tight bull flag pattern in its bullrun after the earnings report was a two line beat much like the one a quarter ago. VERX has impressed traders including this one who got in on the ride early. I will trade this like others recently with a similar pattern. I will hold during the consolidation and watch for a break above the flag regression channel. I will add upon the break and set a trailing stop loss of 5% upon a rise of another 5% keeping the profits safe while underway. See my ideas on SOUN DUOL, VTYX and a few others. Review the link to the pattern description here. See also my swing long trade ideas for this sector XBI and LABU.
NASDAQ:VERX
by AwesomeAvani